-+ 0.00%
-+ 0.00%
-+ 0.00%

Faeth Therapeutics wins FDA fast-track status for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer

PUBT·08/17/2026 11:31:47
Listen to the news
Faeth Therapeutics wins FDA fast-track status for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer
  • Faeth Therapeutics received FDA Fast Track designation for PIKTOR with paclitaxel in biomarker-selected advanced or recurrent endometrial cancer.
  • No clinical results were reported or scheduled for presentation in the announcement.
  • Fast Track status supports a faster regulatory path for patients whose disease progressed on platinum chemotherapy and an immune checkpoint inhibitor.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260817276941) on August 17, 2026, and is solely responsible for the information contained therein.